GlobeImmune Inc., a Louisville, Colo.-based developer of immunotherapy products for the treatment of cancer and chronic infectious diseases, has raised $41.2 million in Series C funding.
Wexford Capital led the deal, and was joined by Celgene Inc., Mellon Family Investment Co., Richard King Mellon Foundation, Eminent Venture Capital, Boston Life Science Venture and WRF Capital.
Return backers included HealthCare Ventures, Morgenthaler Ventures, Sequel Venture Partners, Lilly Ventures, Medica Venture Partners, Adams Street Partners, Biogen Idec, Inc., Pac-Link Bioventures, China Investment and Development (CIDC), Yasuda Enterprise Development, Partners Healthcare and GC&H Investments. GlobeImmune has now raised $88 million in total VC funding. www.globeimmune.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.